Teva’s MS pill misses the mark in PhIII trial

9th May 2017 Uncategorised 0

Teva Pharmaceutical Industries and partner Active Biotech say a late-stage trial of laquinimod has missed its primary endpoint, with the drug failing to halt the progression of multiple sclerosis in patients with relapsing remitting forms of the disease (RRMS).

More: Teva’s MS pill misses the mark in PhIII trial
Source: News